

Christian Klein

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1242106/publications.pdf>

Version: 2024-02-01

282
papers

16,809
citations

28274

55
h-index

16650

123
g-index

304
all docs

304
docs citations

304
times ranked

21698
citing authors

#	ARTICLE	IF	CITATIONS
1	In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2. <i>Science</i> , 2004, 303, 844-848.	12.6	4,204
2	A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade. <i>Nature Medicine</i> , 2018, 24, 994-1004.	30.7	783
3	Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. <i>Blood</i> , 2010, 115, 4393-4402.	1.4	782
4	Angiopoietin-2 differentially regulates angiogenesis through TIE2 and integrin signaling. <i>Journal of Clinical Investigation</i> , 2012, 122, 1991-2005.	8.2	376
5	Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 11187-11192.	7.1	367
6	Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab <i>In Vitro</i> and in Xenograft Models. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 2031-2042.	4.1	301
7	Progression of Lung Cancer Is Associated with Increased Dysfunction of T Cells Defined by Coexpression of Multiple Inhibitory Receptors. <i>Cancer Immunology Research</i> , 2015, 3, 1344-1355.	3.4	285
8	Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties. <i>MAbs</i> , 2013, 5, 22-33.	5.2	280
9	Chalcone Derivatives Antagonize Interactions between the Human Oncoprotein MDM2 and p53. <i>Biochemistry</i> , 2001, 40, 336-344.	2.5	279
10	A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors. <i>Clinical Cancer Research</i> , 2016, 22, 3286-3297.	7.0	260
11	Target Expression, Generation, Preclinical Activity, and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM801 for Multiple Myeloma Treatment. <i>Cancer Cell</i> , 2017, 31, 396-410.	16.8	251
12	p53 Contains Large Unstructured Regions in its Native State. <i>Journal of Molecular Biology</i> , 2002, 322, 917-927.	4.2	242
13	Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	229
14	Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions. <i>Protein Engineering, Design and Selection</i> , 2016, 29, 457-466.	2.1	226
15	The N-terminal Domain of p53 is Natively Unfolded. <i>Journal of Molecular Biology</i> , 2003, 332, 1131-1141.	4.2	225
16	WT p53, but Not Tumor-derived Mutants, Bind to Bcl2 via the DNA Binding Domain and Induce Mitochondrial Permeabilization. <i>Journal of Biological Chemistry</i> , 2006, 281, 8600-8606.	3.4	208
17	Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab. <i>Blood</i> , 2013, 122, 3482-3491.	1.4	206
18	Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies. <i>Blood</i> , 2011, 118, 358-367.	1.4	203

#	ARTICLE	IF	CITATIONS
19	Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines. <i>Oncolimmunology</i> , 2017, 6, e1277306.	4.6	190
20	Targeting key angiogenic pathways with a bispecific Cross <sc>MA</sc> b optimized for neovascular eye diseases. <i>EMBO Molecular Medicine</i> , 2016, 8, 1265-1288.	6.9	185
21	Ang-2-VEGF-A CrossMab, a Novel Bispecific Human IgG1 Antibody Blocking VEGF-A and Ang-2 Functions Simultaneously, Mediates Potent Antitumor, Antiangiogenic, and Antimetastatic Efficacy. <i>Clinical Cancer Research</i> , 2013, 19, 6730-6740.	7.0	179
22	Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	178
23	Targeting the p53â€“MDM2 interaction to treat cancer. <i>British Journal of Cancer</i> , 2004, 91, 1415-1419.	6.4	177
24	Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies. <i>MAbs</i> , 2012, 4, 653-663.	5.2	168
25	CD20-TCB with Obinutuzumab Pretreatment as Next-Generation Treatment of Hematologic Malignancies. <i>Clinical Cancer Research</i> , 2018, 24, 4785-4797.	7.0	146
26	The use of CrossMAB technology for the generation of bi- and multispecific antibodies. <i>MAbs</i> , 2016, 8, 1010-1020.	5.2	132
27	A long-lived IL-2 mutein that selectively activates and expands regulatory T cells as a therapy for autoimmune disease. <i>Journal of Autoimmunity</i> , 2018, 95, 1-14.	6.5	129
28	A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies. <i>Advances in Therapy</i> , 2017, 34, 324-356.	2.9	128
29	Glycoengineering of Therapeutic Antibodies Enhances Monocyte/Macrophage-Mediated Phagocytosis and Cytotoxicity. <i>Journal of Immunology</i> , 2014, 192, 2252-2260.	0.8	127
30	Preclinical Studies on the Mechanism of Action and the Anti-Lymphoma Activity of the Novel Anti-CD20 Antibody GA101. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 178-185.	4.1	125
31	Obinutuzumab induces superior B-cell cytotoxicity to rituximab in rheumatoid arthritis and systemic lupus erythematosus patient samples. <i>Rheumatology</i> , 2017, 56, 1227-1237.	1.9	124
32	Comparison of the <i>in vitro</i> effects of the antiâ€“CD20 antibodies rituximab and GA101 on chronic lymphocytic leukaemia cells. <i>British Journal of Haematology</i> , 2011, 152, 295-306.	2.5	118
33	A novel three-dimensional heterotypic spheroid model for the assessment of the activity of cancer immunotherapy agents. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 129-140.	4.2	112
34	Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial. <i>Blood</i> , 2019, 133, 1964-1976.	1.4	104
35	A human immunodeficiency syndrome caused by mutations in CARMIL2. <i>Nature Communications</i> , 2017, 8, 14209.	12.8	103
36	RG7386, a Novel Tetravalent FAP-DR5 Antibody, Effectively Triggers FAP-Dependent, Avidity-Driven DR5 Hyperclustering and Tumor Cell Apoptosis. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 946-957.	4.1	99

#	ARTICLE	IF	CITATIONS
37	p53 A Natural Cancer Killer: Structural Insights and Therapeutic Concepts. <i>Angewandte Chemie - International Edition</i> , 2006, 45, 6440-6460.	13.8	98
38	CEA TCB: A novel head-to-tail 2:1 T cell bispecific antibody for treatment of CEA-positive solid tumors. <i>Oncology</i> , 2016, 5, e1203498.	4.6	94
39	Targeting Macrophages Sensitizes Chronic Lymphocytic Leukemia to Apoptosis and Inhibits Disease Progression. <i>Cell Reports</i> , 2016, 14, 1748-1760.	6.4	90
40	Engineering therapeutic bispecific antibodies using CrossMab technology. <i>Methods</i> , 2019, 154, 21-31.	3.8	89
41	Sustained in vivo signaling by long-lived IL-2 induces prolonged increases of regulatory T cells. <i>Journal of Autoimmunity</i> , 2015, 56, 66-80.	6.5	87
42	Human neutrophils mediate trogocytosis rather than phagocytosis of CLL B cells opsonized with anti-CD20 antibodies. <i>Blood</i> , 2017, 129, 2636-2644.	1.4	86
43	Immuno-PET and Immuno-SPECT of Rheumatoid Arthritis with Radiolabeled Anti-Fibroblast Activation Protein Antibody Correlates with Severity of Arthritis. <i>Journal of Nuclear Medicine</i> , 2015, 56, 778-783.	5.0	84
44	Obinutuzumab (GA101) compared to rituximab significantly enhances cell death and antibody-dependent cytotoxicity and improves overall survival against CD20+ rituximab-sensitive/-resistant Burkitt lymphoma (BL) and precursor B-acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2015, 171, 763-775.	2.5	83
45	NMR Spectroscopy Reveals the Solution Dimerization Interface of p53 Core Domains Bound to Their Consensus DNA. <i>Journal of Biological Chemistry</i> , 2001, 276, 49020-49027.	3.4	75
46	BclxL Changes Conformation upon Binding to Wild-type but Not Mutant p53 DNA Binding Domain. <i>Journal of Biological Chemistry</i> , 2010, 285, 3439-3450.	3.4	70
47	KIR/HLA Interactions Negatively Affect Rituximab- but Not GA101 (Obinutuzumab)-Induced Antibody-Dependent Cellular Cytotoxicity. <i>Journal of Immunology</i> , 2014, 192, 5618-5624.	0.8	68
48	Optimized antiangiogenic reprogramming of the tumor microenvironment potentiates CD40 immunotherapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 541-551.	7.1	66
49	High Thermostability and Lack of Cooperative DNA Binding Distinguish the p63 Core Domain from the Homologous Tumor Suppressor p53. <i>Journal of Biological Chemistry</i> , 2001, 276, 37390-37401.	3.4	63
50	The Low Molecular Weight Proteome of <i>Halobacterium salinarum</i> . <i>Journal of Proteome Research</i> , 2007, 6, 1510-1518.	3.7	63
51	Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia. <i>Blood</i> , 2019, 133, 2765-2775.	1.4	63
52	A Novel Angiopoietin-2 Selective Fully Human Antibody with Potent Anti-Tumoral and Anti-Angiogenic Efficacy and Superior Side Effect Profile Compared to Pan-Angiopoietin-1/-2 Inhibitors. <i>PLoS ONE</i> , 2013, 8, e54923.	2.5	61
53	p95HER2 T cell bispecific antibody for breast cancer treatment. <i>Science Translational Medicine</i> , 2018, 10, .	12.4	59
54	GA101 induces NK-cell activation and antibody-dependent cellular cytotoxicity more effectively than rituximab when complement is present. <i>Leukemia and Lymphoma</i> , 2013, 54, 2500-2505.	1.3	58

#	ARTICLE	IF	CITATIONS
55	<i>In Vivo</i> Fluorescence Imaging of the Activity of CEA TCB, a Novel T-Cell Bispecific Antibody, Reveals Highly Specific Tumor Targeting and Fast Induction of T-Cell-Mediated Tumor Killing. <i>Clinical Cancer Research</i> , 2016, 22, 4417-4427.	7.0	58
56	Enhanced killing of human B-cell lymphoma targets by combined use of cytokine-induced killer cell (CIK) cultures and anti-CD20 antibodies. <i>Blood</i> , 2011, 117, 510-518.	1.4	57
57	Angiopoietin-2 Inhibition Rescues Arteriovenous Malformation in a Smad4 Hereditary Hemorrhagic Telangiectasia Mouse Model. <i>Circulation</i> , 2019, 139, 2049-2063.	1.6	57
58	A novel bispecific EGFR/Met antibody blocks tumor-promoting phenotypic effects induced by resistance to EGFR inhibition and has potent antitumor activity. <i>Oncogene</i> , 2013, 32, 5593-5601.	5.9	53
59	Boosting T cell-mediated antibody-dependent cellular cytotoxicity by PD-1 blockade in follicular lymphoma. <i>Oncotarget</i> , 2019, 8, 1554175.	4.6	53
60	Simlukafusp alfa (FAP-IL2v) immunocytokine is a versatile combination partner for cancer immunotherapy. <i>MAbs</i> , 2021, 13, 1913791.	5.2	53
61	Obinutuzumab in hematologic malignancies: Lessons learned to date. <i>Cancer Treatment Reviews</i> , 2015, 41, 784-792.	7.7	52
62	DNA hypomethylating agents increase activation and cytolytic activity of CD8+ T cells. <i>Molecular Cell</i> , 2021, 81, 1469-1483.e8.	9.7	52
63	Deconstruction of a Nutlin: Dissecting the Binding Determinants of a Potent Protein-Protein Interaction Inhibitor. <i>ACS Medicinal Chemistry Letters</i> , 2013, 4, 660-665.	2.8	51
64	New insights in Type I and Type II CD20 antibody mechanisms of action with a panel of novel CD20 antibodies. <i>British Journal of Haematology</i> , 2018, 180, 808-820.	2.5	51
65	Prediction of the Optimal Dosing Regimen Using a Mathematical Model of Tumor Uptake for Immunocytokine-Based Cancer Immunotherapy. <i>Clinical Cancer Research</i> , 2018, 24, 3325-3333.	7.0	51
66	Obinutuzumab (GA101) for the Treatment of Chronic Lymphocytic Leukemia and Other B-Cell Non-Hodgkin's Lymphomas: A Glycoengineered Type II CD20 Antibody. <i>Oncology Research and Treatment</i> , 2015, 38, 185-192.	1.2	49
67	Prognostic Impact of Natural Killer Cell Count in Follicular Lymphoma and Diffuse Large B-cell Lymphoma Patients Treated with Immunochemotherapy. <i>Clinical Cancer Research</i> , 2019, 25, 4634-4643.	7.0	49
68	A Novel Glycoengineered Bispecific Antibody Format for Targeted Inhibition of Epidermal Growth Factor Receptor (EGFR) and Insulin-like Growth Factor Receptor Type I (IGF-1R) Demonstrating Unique Molecular Properties. <i>Journal of Biological Chemistry</i> , 2014, 289, 18693-18706.	3.4	48
69	Anti-tumor activity of obinutuzumab and rituximab in a follicular lymphoma 3D model. <i>Blood Cancer Journal</i> , 2013, 3, e131-e131.	6.2	46
70	Cooperative Binding of p53 to DNA: Regulation by Protein-Protein Interactions through a Double Salt Bridge. <i>Angewandte Chemie - International Edition</i> , 2005, 44, 5247-5251.	13.8	45
71	CD40 stimulation sensitizes CLL cells to lysosomal cell death induction by type II anti-CD20 mAb GA101. <i>Blood</i> , 2011, 118, 5178-5188.	1.4	44
72	Development of tetravalent IgG1 dual targeting IGF-1R-EGFR antibodies with potent tumor inhibition. <i>Archives of Biochemistry and Biophysics</i> , 2012, 526, 206-218.	3.0	44

#	ARTICLE	IF	CITATIONS
73	Enhanced anti-tumor activity of the glycoengineered type II CD20 antibody obinutuzumab (GA101) in combination with chemotherapy in xenograft models of human lymphoma. <i>Leukemia and Lymphoma</i> , 2014, 55, 2151-5160.	1.3	44
74	Activatory and Inhibitory Fc γ 3 Receptors Augment Rituximab-mediated Internalization of CD20 Independent of Signaling via the Cytoplasmic Domain. <i>Journal of Biological Chemistry</i> , 2015, 290, 5424-5437.	3.4	44
75	An NMR-Based Antagonist Induced Dissociation Assay for Targeting the Ligand-Protein and Protein-Protein Interactions in Competition Binding Experiments. <i>Journal of Medicinal Chemistry</i> , 2007, 50, 4382-4387.	6.4	43
76	Protease-activation using anti-idiotypic masks enables tumor specificity of a folate receptor 1-T cell bispecific antibody. <i>Nature Communications</i> , 2020, 11, 3196.	12.8	43
77	Targeting intracellular WT1 in AML with a novel RMF-peptide-MHC-specific T-cell bispecific antibody. <i>Blood</i> , 2021, 138, 2655-2669.	1.4	43
78	Molecular characterization of novel trispecific ErbB-cMet-IGF1R antibodies and their antigen-binding properties. <i>Protein Engineering, Design and Selection</i> , 2012, 25, 551-560.	2.1	40
79	Combining chemotherapeutic agents and netrin-1 interference potentiates cancer cell death. <i>EMBO Molecular Medicine</i> , 2013, 5, 1821-1834.	6.9	39
80	Efficacy of phosphatidylinositol-3 kinase inhibitors with diverse isoform selectivity profiles for inhibiting the survival of chronic lymphocytic leukemia cells. <i>International Journal of Cancer</i> , 2015, 137, 2234-2242.	5.1	39
81	Trabectedin Reveals a Strategy of Immunomodulation in Chronic Lymphocytic Leukemia. <i>Cancer Immunology Research</i> , 2019, 7, 2036-2051.	3.4	39
82	Novel 3rd Generation Humanized Type II CD20 Antibody with Glycoengineered Fc and Modified Elbow Hinge for Enhanced ADCC and Superior Apoptosis Induction.. <i>Blood</i> , 2006, 108, 229-229.	1.4	39
83	Monitoring Therapy Response of Experimental Arthritis with Radiolabeled Tracers Targeting Fibroblasts, Macrophages, or Integrin α v β 3. <i>Journal of Nuclear Medicine</i> , 2016, 57, 467-472.	5.0	38
84	Combining the best of two worlds: highly flexible chimeric antigen receptor adaptor molecules (CAR-adaptors) for the recruitment of chimeric antigen receptor T cells. <i>MAbs</i> , 2019, 11, 621-631.	5.2	38
85	A TLR7 agonist enhances the antitumor efficacy of obinutuzumab in murine lymphoma models via NK cells and CD4 T cells. <i>Leukemia</i> , 2017, 31, 1611-1621.	7.2	37
86	Targeting of fibroblast activation protein in rheumatoid arthritis patients: imaging and <i>ex vivo</i> photodynamic therapy. <i>Rheumatology</i> , 2022, 61, 2999-3009.	1.9	37
87	High-affinity CD16-polymorphism and Fc-engineered antibodies enable activity of CD16-chimeric antigen receptor-modified T cells for cancer therapy. <i>British Journal of Cancer</i> , 2019, 120, 79-87.	6.4	36
88	Fibroblast activation protein-targeted-4-1BB ligand agonist amplifies effector functions of intratumoral T cells in human cancer. , 2020, 8, e000238.		35
89	Selective Bispecific T Cell Recruiting Antibody and Antitumor Activity of Adoptive T Cell Transfer. <i>Journal of the National Cancer Institute</i> , 2015, 107, 364.	6.3	34
90	Ten years in the making: application of CrossMab technology for the development of therapeutic bispecific antibodies and antibody fusion proteins. <i>MAbs</i> , 2021, 13, 1967714.	5.2	34

#	ARTICLE	IF	CITATIONS
91	Human immunocompetent Organ-on-Chip platforms allow safety profiling of tumor-targeted T-cell bispecific antibodies. <i>ELife</i> , 2021, 10, .	6.0	33
92	Liposomal Treatment of Experimental Arthritis Can Be Monitored Noninvasively with a Radiolabeled Anti- α -Fibroblast Activation Protein Antibody. <i>Journal of Nuclear Medicine</i> , 2017, 58, 151-155.	5.0	32
93	Bispecific Antibodies Enable Synthetic Agonistic Receptor-Transduced T Cells for Tumor Immunotherapy. <i>Clinical Cancer Research</i> , 2019, 25, 5890-5900.	7.0	31
94	Crystal Structure of an Anti-Ang2 CrossFab Demonstrates Complete Structural and Functional Integrity of the Variable Domain. <i>PLoS ONE</i> , 2013, 8, e61953.	2.5	30
95	The PET-Tracer ^{89}Zr -Df-IAB22M2C Enables Monitoring of Intratumoral CD8 T-cell Infiltrates in Tumor-Bearing Humanized Mice after T-cell Bispecific Antibody Treatment. <i>Cancer Research</i> , 2020, 80, 2903-2913.	0.9	30
96	A Human Neutralizing Antibody Specific to Ang-2 Inhibits Ocular Angiogenesis. <i>Microcirculation</i> , 2011, 18, 598-607.	1.8	29
97	Heavy and light chain pairing of bivalent quadroma and knobs-into-holes antibodies analyzed by UHR-ESI-QTOF mass spectrometry. <i>MABs</i> , 2016, 8, 49-55.	5.2	29
98	Acquired cancer cell resistance to T cell bispecific antibodies and CAR T targeting HER2 through JAK2 down-modulation. <i>Nature Communications</i> , 2021, 12, 1237.	12.8	29
99	Recombinant Human IL-15 Trans-Presentation by B Leukemic Cells from Chronic Lymphocytic Leukemia Induces Autologous NK Cell Proliferation Leading to Improved Anti-CD20 Immunotherapy. <i>Journal of Immunology</i> , 2013, 191, 3634-3640.	0.8	28
100	Application of a MABEL Approach for a T-Cell-Bispecific Monoclonal Antibody: CEA TCB. <i>Journal of Immunotherapy</i> , 2016, 39, 279-289.	2.4	28
101	XGFR*, a novel affinity-matured bispecific antibody targeting IGF-1R and EGFR with combined signaling inhibition and enhanced immune activation for the treatment of pancreatic cancer. <i>MABs</i> , 2016, 8, 811-827.	5.2	28
102	Combination of T-Cell Bispecific Antibodies With PD-L1 Checkpoint Inhibition Elicits Superior Anti-Tumor Activity. <i>Frontiers in Oncology</i> , 2020, 10, 575737.	2.8	28
103	Stromal FAP is an independent poor prognosis marker in non-small cell lung adenocarcinoma and associated with p53 mutation. <i>Lung Cancer</i> , 2021, 155, 10-19.	2.0	28
104	Expression of inhibitory receptors on intratumoral T cells modulates the activity of a T cell-bispecific antibody targeting folate receptor. <i>OncImmunology</i> , 2016, 5, e1062969.	4.6	27
105	Endogenous IL-8 acts as a CD16 co-activator for natural killer-mediated anti-CD20 B cell depletion in chronic lymphocytic leukemia. <i>Leukemia Research</i> , 2013, 37, 440-446.	0.8	24
106	Avadomide plus obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (CC-122-NHL-001): a multicentre, dose escalation and expansion phase 1 study. <i>Lancet Haematology</i> , 2020, 7, e649-e659.	4.6	24
107	Anti-CD20 treatment for B-cell malignancies: current status and future directions. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 161-181.	3.1	24
108	A modular and controllable T cell therapy platform for acute myeloid leukemia. <i>Leukemia</i> , 2021, 35, 2243-2257.	7.2	24

#	ARTICLE	IF	CITATIONS
109	Proteophosphoglycans of <i>Leishmania mexicana</i> : Molecular cloning and characterization of the <i>Leishmania mexicana</i> ppg2 gene encoding the proteophosphoglycans aPPG and pPPG2 that are secreted by amastigotes and promastigotes. <i>Biochemical Journal</i> , 1999, 344, 787-795.	3.7	23
110	Shortâ€hairpinâ€RNAâ€mediated silencing of fucosyltransferase 8 in Chineseâ€hamster ovary cells for the production of antibodies with enhanced antibody immune effector function. <i>Biotechnology and Applied Biochemistry</i> , 2009, 53, 31-37.	3.1	23
111	Antitumour activity of the glycoengineered type <sc>II</sc> antiâ€CD<sc>20</sc> antibody obinutuzumab (<sc>GA</sc>101) in combination with the <sc>MDM</sc>2â€selective antagonist idasanutlin (<sc>RG</sc>7388). <i>European Journal of Haematology</i> , 2016, 97, 461-470.	2.2	23
112	The Type II Antiâ€CD20 Antibody Obinutuzumab (GA101) Is More Effective Than Rituximab at Depleting B Cells and Treating Disease in a Murine Lupus Model. <i>Arthritis and Rheumatology</i> , 2021, 73, 826-836.	5.6	23
113	TetraMabs: simultaneous targeting of four oncogenic receptor tyrosine kinases for tumor growth inhibition in heterogeneous tumor cell populations. <i>Protein Engineering, Design and Selection</i> , 2016, 29, 467-475.	2.1	22
114	Imaging fibroblast activation protein to monitor therapeutic effects of neutralizing interleukin-22 in collagen-induced arthritis. <i>Rheumatology</i> , 2018, 57, 737-747.	1.9	22
115	Variable heavyâ€variable light domain and Fab-arm CrossMabs with charged residue exchanges to enforce correct light chain assembly. <i>Protein Engineering, Design and Selection</i> , 2018, 31, 289-299.	2.1	22
116	A Tridimensional Model for NK Cell-Mediated ADCC of Follicular Lymphoma. <i>Frontiers in Immunology</i> , 2019, 10, 1943.	4.8	22
117	Targeted photodynamic therapy selectively kills activated fibroblasts in experimental arthritis. <i>Rheumatology</i> , 2020, 59, 3952-3960.	1.9	22
118	Cross-linking of T cell to B cell lymphoma by the T cell bispecific antibody CD20-TCB induces IFN γ /CXCL10-dependent peripheral T cell recruitment in humanized murine model. <i>PLoS ONE</i> , 2021, 16, e0241091.	2.5	22
119	CD20 Tcb (RG6026), a Novel "2:1" T Cell Bispecific Antibody for the Treatment of B Cell Malignancies. <i>Blood</i> , 2016, 128, 1836-1836.	1.4	22
120	Sensitive Detection of the Natural Killer Cell-Mediated Cytotoxicity of Anti-CD20 Antibodies and Its Impairment by B-Cell Receptor Pathway Inhibitors. <i>BioMed Research International</i> , 2018, 2018, 1-9.	1.9	20
121	Antibodies against CD20 or B-Cell Receptor Induce Similar Transcription Patterns in Human Lymphoma Cell Lines. <i>PLoS ONE</i> , 2011, 6, e16596.	2.5	20
122	Committing Cytomegalovirus-Specific CD8 T Cells to Eliminate Tumor Cells by Bifunctional Major Histocompatibility Class I Antibody Fusion Molecules. <i>Cancer Immunology Research</i> , 2015, 3, 764-776.	3.4	19
123	Anti-tumoral, anti-angiogenic and anti-metastatic efficacy of a tetravalent bispecific antibody (TAvi6) targeting VEGF-A and angiopoietin-2. <i>MAbs</i> , 2016, 8, 562-573.	5.2	19
124	A Novel Synthesis of Highly Substituted Perhydropyrrolizines, Perhydroindolizines, and Pyrrolidines: Inhibition of the Peptidyl-Prolylcis/trans Isomerase (PPLase) Pin1. <i>Helvetica Chimica Acta</i> , 2007, 90, 217-259.	1.6	18
125	Solution structure and binding specificity of the p63 DNA binding domain. <i>Scientific Reports</i> , 2016, 6, 26707.	3.3	18
126	Novel carcinoembryonic antigen T-cell bispecific (CEA-TCB) antibody: Preliminary clinical data as a single agent and in combination with atezolizumab in patients with metastatic colorectal cancer (mCRC). <i>Annals of Oncology</i> , 2017, 28, iii151.	1.2	18

#	ARTICLE	IF	CITATIONS
127	GA101, a Novel Humanized Type II CD20 Antibody with Glycoengineered Fc and Enhanced Cell Death Induction, Exhibits Superior Anti-Tumor Efficacy and Superior Tissue B Cell Depletion In Vivo.. Blood, 2007, 110, 2348-2348.	1.4	17
128	Proteophosphoglycans of Leishmania mexicana: Identification, purification, structural and ultrastructural characterization of the secreted promastigote proteophosphoglycan pPPG2, a stage-specific glycoisoform of amastigote aPPG. Biochemical Journal, 1999, 344, 775-786.	3.7	16
129	Bispecific Antibody Derivatives Based on Full-Length IgG Formats. Methods in Molecular Biology, 2012, 901, 247-263.	0.9	16
130	A New Class of Bifunctional Major Histocompatibility Class I Antibody Fusion Molecules to Redirect CD8 T Cells. Molecular Cancer Therapeutics, 2016, 15, 2130-2142.	4.1	15
131	Anti-tumor efficacy study of the Bruton's tyrosine kinase (BTK) inhibitor, ONO/GS-4059, in combination with the glycoengineered type II anti-CD20 monoclonal antibody obinutuzumab (GA101) demonstrates superior <i>in vivo</i> efficacy compared to ONO/GS-4059 in combination with rituximab. Leukemia and Lymphoma. 2017, 58, 699-707.	1.3	15
132	The PI3K-Selective Inhibitor Idelalisib Minimally Interferes with Immune Effector Function Mediated by Rituximab or Obinutuzumab and Significantly Augments B Cell Depletion In Vivo. Journal of Immunology, 2018, 200, 2304-2312.	0.8	15
133	A comparative global phosphoproteomics analysis of obinutuzumab (GA101) versus rituximab (RTX) against RTX sensitive and resistant Burkitt lymphoma (BL) demonstrates differential phosphorylation of signaling pathway proteins after treatment. Oncotarget, 2017, 8, 113895-113909.	1.8	15
134	JAK and mTOR inhibitors prevent cytokine release while retaining T cell bispecific antibody in vivo efficacy. , 2022, 10, e003766.		15
135	Novel strategies for the mitigation of cytokine release syndrome induced by T cell engaging therapies with a focus on the use of kinase inhibitors. Oncoimmunology, 2022, 11, .	4.6	15
136	Advances in identification and selection of personalized neoantigen/T-cell pairs for autologous adoptive T cell therapies. Oncoimmunology, 2021, 10, 1869389.	4.6	14
137	Src/lck inhibitor dasatinib reversibly switches off cytokine release and T cell cytotoxicity following stimulation with T cell bispecific antibodies. , 2021, 9, e002582.		14
138	Obinutuzumab (GA101) Is Less Prone to Antagonism of Immune Effector Function By Ibrutinib Than Rituximab in Vitro and in Vivo. Blood, 2014, 124, 1765-1765.	1.4	14
139	Dissecting the mechanism of cytokine release induced by T-cell engagers highlights the contribution of neutrophils. Oncoimmunology, 2022, 11, 2039432.	4.6	14
140	Isolation and characterization of glycosylphosphatidylinositol-anchored, mucin-like surface glycoproteins from bloodstream forms of the freshwater-fish parasite Trypanosoma carassii. Biochemical Journal, 2000, 345, 693.	3.7	13
141	214 POSTER Characterization of a recombinant, fully human monoclonal antibody directed against the human insulin-like growth factor-1 receptor. European Journal of Cancer, Supplement, 2006, 4, 66-67.	2.2	13
142	GA101 P329GLALA, a variant of obinutuzumab with abolished ADCC, ADCP and CDC function but retained cell death induction, is as efficient as rituximab in B-cell depletion and antitumor activity. Haematologica, 2018, 103, e78-e81.	3.5	13
143	Pharmacokinetic properties of radiolabeled mutant Interleukin-2v: a PET imaging study. Oncotarget, 2018, 9, 7162-7174.	1.8	13
144	Prognostic Interactions between FAP+ Fibroblasts and CD8+ T Cells in Colon Cancer. Cancers, 2020, 12, 3238.	3.7	13

#	ARTICLE	IF	CITATIONS
145	OUP accepted manuscript. Protein Engineering, Design and Selection, 2017, 30, 649-656.	2.1	13
146	Proteophosphoglycans of Leishmania mexicana. Biochemical Journal, 1999, 344, 775.	3.7	12
147	Response to: Monoclonal antibodies targeting CD20. MAbs, 2013, 5, 337-338.	5.2	12
148	Obinutuzumab (GA101) is highly effective against chronic lymphocytic leukemia cells in ex vivo B-cell depletion irrespective of high-risk prognostic markers. Blood Cancer Journal, 2015, 5, e367-e367.	6.2	12
149	Three-dimensional colon cancer organoids model the response to CEA-CD3 T-cell engagers. Theranostics, 2022, 12, 1373-1387.	10.0	12
150	Abstract 2270: RG7769 (PD1-TIM3), a novel heterodimeric avidity-driven T cell specific PD-1/TIM-3 bispecific antibody lacking Fc-mediated effector functions for dual checkpoint inhibition to reactivate dysfunctional T cells. Cancer Research, 2020, 80, 2270-2270.	0.9	11
151	A human receptor occupancy assay to measure α PD-1 binding in patients with prior α PD-1. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2021, 99, 832-843.	1.5	10
152	Single-nucleotide Fc γ 3 receptor polymorphisms do not impact obinutuzumab/rituximab outcome in patients with lymphoma. Blood Advances, 2021, 5, 2935-2944.	5.2	10
153	Candidate Biomarkers of Response to an Experimental Cancer Drug Identified through a Large-scale RNA Interference Genetic Screen. Clinical Cancer Research, 2009, 15, 5811-5819.	7.0	9
154	Biochemical and biophysical characterization of purified native CD20 alone and in complex with rituximab and obinutuzumab. Scientific Reports, 2019, 9, 13675.	3.3	9
155	Novel Tumor-Targeted, Engineered IL-2 Variant (IL2v)-Based Immunocytokines For Immunotherapy Of Cancer. Blood, 2013, 122, 2278-2278.	1.4	9
156	Disparity in peripheral and renal B-cell depletion with rituximab in systemic lupus erythematosus: an opportunity for obinutuzumab?. Rheumatology, 2022, 61, 2894-2904.	1.9	9
157	Fibroblast Activation Protein Targeted Photodynamic Therapy Selectively Kills Activated Skin Fibroblasts from Systemic Sclerosis Patients and Prevents Tissue Contraction. International Journal of Molecular Sciences, 2021, 22, 12681.	4.1	9
158	Proteophosphoglycans of Leishmania mexicana. Biochemical Journal, 1999, 344, 787.	3.7	8
159	Response: novel lysosomal-dependent cell death following homotypic adhesion occurs within cell aggregates. Blood, 2010, 116, 3373-3374.	1.4	8
160	How to outsmart NK cell tolerance. OncoImmunology, 2015, 4, e1016708.	4.6	8
161	Chemotherapy-free, triple combination of obinutuzumab, venetoclax and idasanutlin: antitumor activity in xenograft models of non-Hodgkin lymphoma. Leukemia and Lymphoma, 2018, 59, 1482-1485.	1.3	8
162	DuoMab: a novel CrossMab-based IgG-derived antibody format for enhanced antibody-dependent cell-mediated cytotoxicity. MAbs, 2019, 11, 1402-1414.	5.2	8

#	ARTICLE	IF	CITATIONS
163	CD16 pre-ligation by defucosylated tumor-targeting mAb sensitizes human NK cells to ^{13}C cytokine stimulation via PI3K/mTOR axis. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 501-512.	4.2	8
164	Proteolysis-Targeting Chimeras Enhance T Cell Bispecific Antibody-Driven T Cell Activation and Effector Function through Increased MHC Class I Antigen Presentation in Cancer Cells. <i>Journal of Immunology</i> , 2021, 207, 493-504.	0.8	8
165	Development of Bispecific Molecules for the In Situ Detection of Protein-Protein Interactions and Protein Phosphorylation. <i>Chemistry and Biology</i> , 2014, 21, 357-368.	6.0	7
166	S41. Novel CEA-targeted IL2 variant immunocytokine for immunotherapy of cancer. , 2014, 2, .		7
167	Targeting key angiogenic pathways with a bispecific Cross<sc>MA</sc>b optimized for neovascular eye diseases. <i>EMBO Molecular Medicine</i> , 2017, 9, 985-985.	6.9	7
168	Vaccine-induced CD8 T cells are redirected with peptide-MHC class I-IgG antibody fusion proteins to eliminate tumor cells in vivo. <i>MAbs</i> , 2020, 12, 1834818.	5.2	7
169	Prognostic significance of <i>FCGR2B</i> expression for the response of DLBCL patients to rituximab or obinutuzumab treatment. <i>Blood Advances</i> , 2021, 5, 2945-2957.	5.2	7
170	RG6076 (CD19-4-1BBL): CD19-Targeted 4-1BB Ligand Combination with Glofitamab As an Off-the-Shelf, Enhanced T-Cell Redirection Therapy for B-Cell Malignancies. <i>Blood</i> , 2020, 136, 40-40.	1.4	7
171	Combination therapy with the type II anti-CD20 antibody obinutuzumab. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 1145-1162.	4.1	6
172	P329G-CAR-J: a novel Jurkat-NFAT-based CAR-T reporter system recognizing the P329G Fc mutation. <i>Protein Engineering, Design and Selection</i> , 2019, 32, 207-218.	2.1	6
173	Co-Stimulatory versus Cell Death Aspects of Agonistic CD40 Monoclonal Antibody Selicrelumab in Chronic Lymphocytic Leukemia. <i>Cancers</i> , 2021, 13, 3084.	3.7	6
174	Combination of the glycoengineered Type II CD20 antibody obinutuzumab (GA101) and The novel Bcl-2 selective Inhibitor GDC-0199 Results in superior In Vitro and In Vivo Anti-tumor activity in models Of B-Cell Malignancies. <i>Blood</i> , 2013, 122, 4412-4412.	1.4	6
175	Prodrug-Activating Chain Exchange (PACE) converts targeted prodrug derivatives to functional bi- or multispecific antibodies. <i>Biological Chemistry</i> , 2022, 403, 495-508.	2.5	6
176	Backbone 1H, 13C and 15N resonance assignments for the 25.8 kDa DNA binding domain of the human p63 protein. <i>Journal of Biomolecular NMR</i> , 2003, 26, 377-378.	2.8	5
177	In vitro folding and characterization of the p53 DNA binding domain. <i>Biological Chemistry</i> , 2004, 385, 95-102.	2.5	5
178	Superior Efficacy of the Novel Type II, Glycoengineered CD20 Antibody GA101 vs. the Type I CD20 Antibodies Rituximab and Ofatumumab. <i>Blood</i> , 2010, 116, 3925-3925.	1.4	5
179	The PI3K Delta Selective Inhibitor Idelalisib Minimally Interferes with Immune Effector Function and B Cell Depletion Mediated By Obinutuzumab (GA101) and Rituximab. <i>Blood</i> , 2014, 124, 3342-3342.	1.4	5
180	Abstract LB-389: Combination of TYRP1-TCB, a novel T cell bispecific antibody for the treatment of melanoma, with immunomodulatory agents. , 2020, , .		5

#	ARTICLE	IF	CITATIONS
181	Abstract 1552: A novel PD1-IL2v immunocytokine for preferential <i>cis</i> -activation of IL-2R signaling on PD-1 expressing T cell subsets strongly potentiates anti-tumor T cell activity of PD-1 checkpoint inhibition and IL-2R-beta-gamma agonism. <i>Cancer Research</i> , 2019, 79, 1552-1552.	0.9	4
182	A New Class of T-Cell Bispecific Antibodies for the Treatment of Multiple Myeloma, Binding to B Cell Maturation Antigen and CD3 and Showing Potent, Specific Antitumor Activity in Myeloma Cells and Long Duration of Action in Cynomolgus Monkeys. <i>Blood</i> , 2015, 126, 2998-2998.	1.4	4
183	Obinutuzumab (GA101) vs. rituximab significantly enhances cell death, antibody-dependent cytotoxicity and improves overall survival against CD20+ primary mediastinal B-cell lymphoma (PMBL) in a xenograft NOD-scid IL2Rgnull (NSG) mouse model: a potential targeted agent in the treatment of PMBL. <i>Oncotarget</i> , 2020, 11, 3035-3047.	1.8	4
184	Targeting Intracellular WT1 in AML Utilizing a T Cell Bispecific Antibody Construct: Augmenting Efficacy through Combination with Lenalidomide. <i>Blood</i> , 2019, 134, 4450-4450.	1.4	4
185	Pharmacokinetics and Pharmacodynamics of T-Cell Bispecifics in the Tumour Interstitial Fluid. <i>Pharmaceutics</i> , 2021, 13, 2105.	4.5	4
186	PKPD Assessment of the Anti-CD20 Antibody Obinutuzumab in Cynomolgus Monkey is Feasible Despite Marked Anti-Drug Antibody Response in This Species. <i>Journal of Pharmaceutical Sciences</i> , 2019, 108, 3729-3736.	3.3	3
187	Calcium Channel Blockers Impair the Antitumor Activity of Anti-CD20 Monoclonal Antibodies by Blocking EGR-1 Induction. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 2371-2381.	4.1	3
188	Editorial: Bispecific Antibodies for T-Cell Based Immunotherapy. <i>Frontiers in Oncology</i> , 2020, 10, 628005.	2.8	3
189	Abstract 3629: Engineering a novel asymmetric head-to-tail 2+1 T-cell bispecific (2+1 TCB) IgG antibody platform with superior T-cell killing compared to 1+1 asymmetric TCBs. , 2017, , .		3
190	Abstract 3634: A novel tumor-targeted 4-1BB agonist and its combination with T-cell bispecific antibodies: an off-the-shelf cancer immunotherapy alternative to CAR T-cells. , 2017, , .		3
191	Polatuzumab Vedotin, an Antibody-Drug Conjugate Targeting CD79b, Is a Highly Active Agent Against Burkitt Lymphoma and Primary Mediastinal B-Cell Lymphoma. <i>Blood</i> , 2019, 134, 3963-3963.	1.4	3
192	Enhanced Activity of GA101, a Novel Type II, Glycoengineered CD20 Antibody, In Combination with Bendamustine or Fludarabine, and with the Bcl-2 Family Inhibitors ABT-737 or ABT-263. <i>Blood</i> , 2010, 116, 3915-3915.	1.4	3
193	Abstract 2217: Combining CEA-IL2v and FAP-IL2v immunocytokines with PD-L1 checkpoint blockade. <i>Cancer Research</i> , 2016, 76, 2217-2217.	0.9	3
194	Abstract 6135: Tumor-bearing non-human primates: An unrivaled model for translational cancer immunology research. , 2020, , .		3
195	653â€¦Dasatinib as a rapid pharmacological ON/OFF switch for T cell bispecific antibody-induced T cell activation and cytokine release. , 2020, , .		3
196	504 POSTER GA101, a therapeutic glycoengineered CD20 antibody recognizing a type II epitope mediates outstanding anti-tumor efficacy in Non-Hodgkin lymphoma xenograft models and superior B cell depletion. <i>European Journal of Cancer, Supplement</i> , 2008, 6, 160.	2.2	2
197	OP0159â€¦Improving B-Cell Depletion in Rheumatoid Arthritis and Systemic Lupus Erythematosus: Resistance To Rituximab and The Potential of Obinutuzumab. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 116.1-116.	0.9	2
198	141â€¦PBMC-based cancer vaccines generated with microfluidics squeezing demonstrate synergistic and durable tumor reduction in combination with PD1 checkpoint and FAP targeted IL-2 variants. , 2020, , .		2

#	ARTICLE	IF	CITATIONS
199	Abstract A245: Combination of the glycoengineered Type II CD20 antibody obinutuzumab (GA101), and the novel Bcl-2 selective inhibitor, ABT-199 (GDC-0199), results in superior in vitro and in vivo anti-tumor activity in models of B-cell malignancies.. , 2013, , .		2
200	Abstract LB-236: M4-3-ML2, a novel glycoengineered humanized IgG1 antibody, targeting a membrane-proximal epitope of MCSP/CSPG4 exhibits potent ADCC induction in vitro and in vivo anti-tumoral efficacy in disseminated melanoma models. , 2012, , .		2
201	Abstract 2027: Novel 3D tumor-immune cell spheroid models for assessment of cancer immunotherapy agents. , 2014, , .		2
202	Abstract 2579: Combination with the novel tumor-targeted CEA-IL2v immunocytokine enhances the activity of ADCC-competent and glycoengineered antibodies in vitro and in vivo. , 2014, , .		2
203	Abstract 650: KIR/HLA interactions negatively affect rituximab, but not GA101 (obinutuzumab)-induced ADCC. , 2014, , .		2
204	Abstract 3658: Dendritic cells dictate the responsiveness of PD-L1 blockade in cancer. , 2017, , .		2
205	Abstract 1788: Enhanced in vitro/in vivo cytotoxicity against Burkitt lymphoma/primary mediastinal large B cell lymphoma by polatuzumab vedotin (hu- anti-CD79b-vc-MMAE, PV) alone or in combination with obinutuzumab. , 2018, , .		2
206	Abstract PR8: Novel tumor-targeted, engineered IL-2 variant (IL-2v)-based immunocytokines for immunotherapy of cancer.. , 2013, , .		2
207	Long-Term Results from a Phase 1b Study of Avadomide in Combination with Obinutuzumab in Patients with Relapsed and/or Refractory B-Cell Non-Hodgkin Lymphoma. Blood, 2020, 136, 41-42.	1.4	2
208	Ibrutinib Exposure and B-Cell Depletion Induced By Anti-CD20 Monoclonal Antibodies Rituximab and Obinutuzumab: Is There a Rationale for Combination Studies?. Blood, 2014, 124, 1980-1980.	1.4	2
209	CLL Cells from Ibrutinib-Induced Lymphocytosis of Relapsed/Refractory Chronic Lymphocytic Leukemia Patients Are Responsive to Obinutuzumab, but Not Rituximab, Ex Vivo. Blood, 2015, 126, 4157-4157.	1.4	2
210	The Triple Combination of the CD20 Antibody Obinutuzumab with the Bcl-2 Inhibitor Venetoclax (GDC-199) and the MDM2 Inhibitor Idasanutlin Results in Superior Efficacy and Long Term Response in Wildtype p53 NHL Tumor Models. Blood, 2016, 128, 4178-4178.	1.4	2
211	A Novel Approach for Quantifying the Pharmacological Activity of T-Cell Engagers Utilizing In Vitro Time Course Experiments and Streamlined Data Analysis. AAPS Journal, 2022, 24, 7.	4.4	2
212	Antikörper – neue Krebsmedikamente. Gezielt wirksame Biomedizin. Chemie in Unserer Zeit, 2009, 43, 328-338.	0.1	1
213	ITOC2 – 037. CEA TCB, A novel T-cell bispecific antibody with potent in vitro and in vivo antitumour activity against solid tumours. European Journal of Cancer, 2015, 51, S13.	2.8	1
214	CAR-J cells for antibody discovery and lead optimization of TCR-like immunoglobulins. MAbs, 2020, 12, 1840709.	5.2	1
215	Abstract 1690: JAK2 downmodulation leads to interferon gamma deficient response and resistance to immunotherapy in breast cancer. , 2021, , .		1
216	Abstract 3285: Ang-2-VEGF CrossMab, a novel bispecific human IgG1 antibody blocking VEGF-A and Ang-2 function mediates potent anti-tumoral and anti-angiogenic efficacy. , 2011, , .		1

#	ARTICLE	IF	CITATIONS
217	Abstract LB-212: XGFR, an Fc-engineered dual signaling inhibitor targeting IGF-1R and EGFR. , 2011, , .		1
218	Abstract 2460: Dissecting the in vitro and in vivo mechanism of action of obinutuzumab (GA101) in preclinical models using an immune effector-dead version of obinutuzumab. , 2015, , .		1
219	Abstract 2774: The triple combination of the FAP-IL2v immunocytokine with PD-L1 checkpoint inhibitory and CD40 agonistic antibodies results in long-term tumor control in the orthotopic PancO2 model. , 2018, , .		1
220	Abstract 5621: FAP-4-1BBL: A novel versatile tumor-stroma targeted 4-1BB agonist for combination immunotherapy with checkpoint inhibitors, T-cell bispecific antibodies, and ADCC-mediating antibodies. , 2018, , .		1
221	Clinical and Biological Characteristics Associated with In Vitro Activity of Anti-CD20 Monoclonal Antibodies, Rituximab and GA101, Against Chronic Lymphocytic Leukemia Cells. Blood, 2010, 116, 2459-2459.	1.4	1
222	Abstract 2592: Tumor targeting and pharmacodynamics of the novel targeted immunocytokine FAP-IL2v in a tumor-bearing Rhesus monkey. , 2014, , .		1
223	Combination of the Glycoengineered Type II CD20 Antibody Obinutuzumab (GA101) and the MDM2 Selective Antagonist RG7388 Results in Superior Anti-Tumor Activity. Blood, 2014, 124, 1780-1780.	1.4	1
224	Abstract 2481: CEA TCB, a novel T-cell bispecific antibody with potent in vitro and in vivo antitumor activity against solid tumors. , 2015, , .		1
225	Abstract 1537: Polatuzumab Vedotin alone or in-combination with anti-CD20 antibody significantly enhanced overall survival in xenografted NSG mice against rituximab sensitive and resistant Burkitt Lymphoma (BL) and Primary Mediastinal B-cell Lymphoma (PMBL). , 2019, , .		1
226	Augmenting Efficacy of T-Cell Bispecific Antibodies in AML through a Tumor Stroma-Targeted 4-1BB Agonist. Blood, 2021, 138, 1178-1178.	1.4	1
227	Lymphoma Microenvironment Deconvolution Links M1 Macrophage Infiltration to Clinical Outcome in Diffuse Large B-Cell Lymphoma. Blood, 2020, 136, 29-30.	1.4	1
228	Optimizing Ex-Vivo Expanded NK Cell- Mediated Antibody-Dependent Cellular Cytotoxicity (ADCC) Combined with NKTR-255 in Chronic Lymphocytic Leukemia (CLL), Follicular Lymphoma (FL), and Burkitt Lymphoma (BL). Blood, 2020, 136, 23-24.	1.4	1
229	[68Ga]Ga-DOTA-Siglec-9 Detects Pharmacodynamic Changes of FAP-Targeted IL2 Variant Immunotherapy in B16-FAP Melanoma Mice. Frontiers in Immunology, 0, 13, .	4.8	1
230	232 Unique molecular recognition of CD20 by the type II CD20 antibody GA101. European Journal of Cancer, Supplement, 2010, 8, 75-76.	2.2	0
231	489 LC06, a novel angiopoietin-2 selective human antibody with potent anti-tumoral and anti-angiogenic efficacy in different xenograft models. European Journal of Cancer, Supplement, 2010, 8, 156-157.	2.2	0
232	1242 POSTER Functional Comparison of IGF-1R Antibodies and Possible Implications for Clinical Safety and Efficacy. European Journal of Cancer, 2011, 47, S157.	2.8	0
233	Glycoengineering of Therapeutic Antibodies. Arzneimittelforschung, 2012, 62, S4-S5.	0.4	0
234	870: A new bispecific T cell recruiting antibody enhances anti-tumor activity of adoptive T cell transfer. European Journal of Cancer, 2014, 50, S213.	2.8	0

#	ARTICLE	IF	CITATIONS
235	A TLR7 agonist enhances the anti-tumour efficacy of obinutuzumab through an NK cell/CD4 dependent mechanism in a murine lymphoma model. <i>European Journal of Cancer</i> , 2016, 61, S211.	2.8	0
236	Activation of cytomegalovirus-specific CD8 ⁺ T-cell response by antibody-mediated peptide-major histocompatibility class I complexes. <i>Oncolmmunology</i> , 2016, 5, e1052930.	4.6	0
237	PD-1 IMMUNE CHECKPOINT BLOCKADE IMPROVES ANTI-CD20 BASED IMMUNOTHERAPY IN FOLLICULAR LYMPHOMA. <i>Hematological Oncology</i> , 2017, 35, 257-258.	1.7	0
238	Arming T cells with activating Fc γ RIIIa receptors for antibody redirected lysis of cancer cells. <i>European Journal of Cancer</i> , 2018, 92, S21.	2.8	0
239	P107â€¦Targeting activated synovial fibroblasts using photodynamic therapy in experimental arthritis. , 2018, , .		0
240	Proof of concept and mode of action of a novel modular platform for adoptive T cell therapy combining bispecific antibodies with synthetic agonistic receptors. <i>European Journal of Cancer</i> , 2018, 92, S19.	2.8	0
241	Mesothelin-targeted bispecific antibodies drive synthetic agonistic receptor â€“ Transduced T cells to mediate specific and conditional therapy of human pancreatic cancer models. <i>European Journal of Cancer</i> , 2018, 92, S20.	2.8	0
242	A novel modular platform for adoptive T cell therapy combining bispecific antibodies with synthetic agonistic receptors. <i>European Journal of Cancer</i> , 2019, 110, S25.	2.8	0
243	Characterization of bispecific antibodies that drive synthetic agonistic receptor - transduced T cells to mediate specific and conditional therapy in human pancreatic cancer models. <i>European Journal of Cancer</i> , 2019, 110, S3.	2.8	0
244	P131â€¦Targeting activated synovial fibroblasts using photodynamic therapy in human rheumatoid arthritis synovial tissue. , 2019, , .		0
245	SAT0052â€¦PHOTODYNAMIC THERAPY TARGETING ACTIVATED FIBROBLASTS INDUCES SYNOVIAL CELL DEATH IN EXPERIMENTAL ARTHRITIS. , 2019, , .		0
246	L4â€¦Synthetic agonistic receptor-activating BiTEs â€“ a modular platform for the efficient targeting of acute myeloid leukemia. , 2020, , .		0
247	P06.01â€¦Bispecific antibody-driven synthetic agonistic receptor â€“ transduced T cells mediate specific and conditional therapy in melanoma cancer models. , 2020, , .		0
248	L2â€¦In vivo live imaging of human T/B cell lymphoma cross-linking mediated by bispecific CD20-TCB antibody. , 2020, 8, A1.2-A1.		0
249	Abstract 3165: Stroma-immune landscape in lymphoma: new mechanisms of immunosuppression and therapeutic targeting. , 2021, , .		0
250	Abstract 71: The immunocytokine PD1-IL2v overcomes immune checkpoint resistance, and combination with an anti-PD-L1 antibody further enhances its anti-tumor activity. , 2021, , .		0
251	WT p53, but not tumor-derived mutants, bind to Bcl2 via the DNA binding domain and induce mitochondrial permeabilization. VOLUME 281 (2006) PAGES 8600-8606. <i>Journal of Biological Chemistry</i> , 2007, 282, 6916.	3.4	0
252	CD40 Stimulation Sensitizes CLL Cells to CD20-Triggered Cell Death by Rituximab and GA101 Via a Different Mechanism. <i>Blood</i> , 2010, 116, 3979-3979.	1.4	0

#	ARTICLE	IF	CITATIONS
253	Enhanced Killing of Human B Lymphoma Targets by Combined Use of Cytokine Induced Killer (CIK) Cultures and Anti-CD20 Antibodies. <i>Blood</i> , 2010, 116, 4285-4285.	1.4	0
254	Anti-Angiogenic Activity of a Tetraivalent Bispecific Antibody (TAVi6) Targeting VEGF and Angiopoietin-2. <i>Blood</i> , 2010, 116, 4304-4304.	1.4	0
255	Abstract LB-397: Functional characterization of IGF-1R antibodies and possible implications for clinical safety and efficacy. , 2011, , .		0
256	Abstract 2319: Dual inhibition of Ang-2 and VEGF via a novel human bispecific bivalent IgG1 CrossMab shows potent anti-angiogenic, antitumoral, and antimetastatic efficacy and leads to a reduced side effect profile compared to single therapies. , 2012, , .		0
257	Obinutuzumab (GA101) Displays Higher Efficiency Than Rituximab in a Follicular Lymphoma 3D Model. <i>Blood</i> , 2012, 120, 4868-4868.	1.4	0
258	Abstract B69: Novel MHC class I antibody fusions for cancer treatment.. , 2013, , .		0
259	Abstract B86: Ang-2-VEGF-A CrossMab, a novel bispecific human IgG1 antibody blocking VEGF-A and Ang-2 functions simultaneously, mediates potent antitumor, antiangiogenic, and antimetastatic efficiency. , 2013, , .		0
260	Abstract LB-264: Development of 3D microtissue models to study the activity of novel tumor-targeted immunotherapeutics.. , 2013, , .		0
261	Abstract 3631: Modulation of monocyte- and macrophage-mediated antibody-dependent cell phagocytosis and cytotoxicity (ADCP/ADCC) by Fc engineering of therapeutic antibodies. , 2014, , .		0
262	ADCC Induced By Monoclonal Anti-CD20 Antibodies in a 3D Follicular Lymphoma model : Signaling and Spatial Localization. <i>Blood</i> , 2014, 124, 3114-3114.	1.4	0
263	Abstract 2479: Obinutuzumab compared to Rituximab significantly enhances cell death, antibody dependent cytotoxicity (ADCC) and improves overall survival against CD20+rituximab-sensitive/-resistant Burkitt Lymphoma (BL) and precursor Lymphoblastic L. , 2015, , .		0
264	Abstract IA07: Enhancing immune effector function via antibody engineering. , 2015, , .		0
265	Comparative Phosphoproteomics Study Between Obinutuzumab (GA101) Vs. Rituximab (RTX) Against RTX Sensitive/Resistant Burkitt Lymphoma (BL): Differentially Phosphorylated B Cell Receptor, Fc-Gamma Receptor, Phagocytosis and Natural Killer Cell-Mediated Cytotoxicity Signaling Pathway Proteins. <i>Blood</i> . 2015. 126. 1550-1550.	1.4	0
266	Abstract 2955: Herceptarg, a novel heterodimeric biparatopic common light chain IgG1 antibody based on trastuzumab and pertuzumab, exerts potent anti-tumoral activity. , 2016, , .		0
267	Abstract 1494: Combination of CEA TCB, a novel T-cell bispecific antibody for the treatment of solid tumors, with PD-L1 checkpoint blockade. , 2016, , .		0
268	Abstract 3893: Obinutuzumab (GA101) versus rituximab against rituximab-sensitive and -resistant Burkitt lymphoma (BL) differentially phosphorylate BCR, Fc-gamma receptor, and natural killer cell-mediated cytotoxicity signaling pathways. , 2016, , .		0
269	Abstract 1594: Enhancement of the anti-tumor activity of CEA TCB via combination with checkpoint blockade by PD-L1 and interleukin-2 variant immunocytokine. , 2017, , .		0
270	Abstract LB-292: p95HER2-T cell bispecific antibody for breast cancer treatment. , 2018, , .		0

#	ARTICLE	IF	CITATIONS
271	Abstract 2565: EBV peptide-derived vaccine significantly enhanced in vitro cytotoxicity against EBV-positive B-cell lymphoma (EBV-BL) treatment using TMV-based delivery system. , 2018, , .		0
272	Abstract 957: Design of CD19-4-1BBL, a novel CD19-targeted 4-1BB ligand for combination therapy with CD20 T-cell bispecific antibodies and CD20 antibodies. , 2018, , .		0
273	Boosting Gamma Delta T Cells-Mediated ADCC By PD-1 Blockade in Follicular Lymphoma. Blood, 2018, 132, 5381-5381.	1.4	0
274	A dual-labeled anti-FAP antibody for imaging and targeted photodynamic therapy of cancer associated fibroblasts in a pancreatic cancer mouse model. Nuklearmedizin - NuclearMedicine, 2019, 58, .	0.7	0
275	PF207 TARGETING WILMS TUMOR 1 WITH A T CELL BISPECIFIC ANTIBODY (WT1â€¦CB): EX VIVO AND IN VIVO POTENCY BY BIVALENT RECOGNITION OF PEPTIDEâ€¦MHC COMPLEXES FROM AN INTRACELLULAR TUMOR ANTIGEN. HemaSphere, 2019, 3, 56.	2.7	0
276	Abstract 1129: Monitoring intratumoral CD8 T cell infiltrates in human stem cell engrafted mice during single agent and combination immunotherapy with T cell bispecific antibodies using the human PET-tracer ⁸⁹ Zr-Df-IAB22M2C. , 2019, , .		0
277	Abstract 4229: Anti-P329G-CAR-T cells as a novel universal CAR-T cell platform. , 2020, , .		0
278	Targeting the p53/MDM2 Pathway for Cancer Therapy. , 2008, , 19-56.		0
279	Abstract PO-26: Prognostic significance of Fc gamma receptor IIB expression in the response of previously untreated diffuse large B-cell lymphomas to anti-CD20 monoclonal antibodies: Differing impact of rituximab and obinutuzumab. , 2020, , .		0
280	Abstract 1129: Monitoring intratumoral CD8 T cell infiltrates in human stem cell engrafted mice during single agent and combination immunotherapy with T cell bispecific antibodies using the human PET-tracer ⁸⁹ Zr-Df-IAB22M2C. , 2019, , .		0
281	Abstract 1537: Polatuzumab Vedotin alone or in-combination with anti-CD20 antibody significantly enhanced overall survival in xenografted NSC mice against rituximab sensitive and resistant Burkitt Lymphoma (BL) and Primary Mediastinal B-cell Lymphoma (PMBL). , 2019, , .		0
282	Abstract 1552: A novel PD1-IL2v immunocytokine for preferential<i>cis</i>-activation of IL-2R signaling on PD-1 expressing T cell subsets strongly potentiates anti-tumor T cell activity of PD-1 checkpoint inhibition and IL-2R-beta-gamma agonism. , 2019, , .		0